USRE42096E1 - Oral pulsed dose drug delivery system - Google Patents
Oral pulsed dose drug delivery system Download PDFInfo
- Publication number
- USRE42096E1 USRE42096E1 US11/091,011 US9101105A USRE42096E US RE42096 E1 USRE42096 E1 US RE42096E1 US 9101105 A US9101105 A US 9101105A US RE42096 E USRE42096 E US RE42096E
- Authority
- US
- United States
- Prior art keywords
- pharmaceutically active
- enteric
- release coating
- amphetamine salts
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- This invention pertains to a multiple dosage form delivery system comprising one or more amphetamine salts for administering the amphetamine salts to a recipient.
- sustained release delivery is not suitable and is affected by the following factors:
- First pass metabolism Some drugs, such as ⁇ blockers, ⁇ -estradiol, and salicylamide, undergo extensive first pass metabolism and require fast drug input to saturate metabolizing enzymes in order to minimize pre-systemic metabolism. Thus, a constant/sustained oral method of delivery would result in reduced oral bioavailability.
- Biological tolerance Continuous release drug plasma profiles are often accompanied by a decline in the pharmacotherapeutic effect of the drug, e.g., biological tolerance of transdermal nitroglycerin.
- Circadian rhythms in certain physiological functions are well established. It has been recognized that many symptoms and onset of disease occur during specific time periods of the 24 hour day, e.g., asthma and angina pectoris attacks are most frequently in the morning hours (1,2).
- Local therapeutic need For the treatment of local disorders such as inflammatory bowel disease, the delivery of compounds to the site of inflammation with no loss due to absorption in the small intestine is highly desirable to achieve the therapeutic effect and to minimize side effects.
- Gastric irritation or drug instability in gastric fluid For compounds with gastric irritation or chemical instability in gastric fluid, the use of a sustained release preparation may exacerbate gastric irritation and chemical instability in gastric fluid.
- Drug absorption differences in various gastrointestinal segments In general, drug absorption is moderately slow in the stomach, rapid in the small intestine, and sharply declining in the large intestine. Compensation for changing absorption characteristics in the gastrointestinal tract may be important for some drugs. For example, it is rational for a delivery system to pump out the drug much faster when the system reaches the distal segment of the intestine, to avoid the entombment of the drug in the feces.
- Pulsed dose delivery systems prepared as either single unit or multiple unit formulations, and which are capable of releasing the drug after a predetermined time, have been studied to address the aforementioned problematic areas for sustained release preparations. These same factors are also problematic in pulsed dose formulation development. For example, gastrointestinal transit times vary not only from patient to patient but also within patients as a result of food intake, stress, and illness; thus a single-unit pulsed-release system may give higher variability compared to a multiple unit system. Additionally, drug layering or core making for multiple unit systems is a time-consuming and hard-to-optimize process. Particularly challenging for formulation scientists has been overcoming two conflicting hurdles for pulsatile formulation development, i.e., lag time and rapid release.
- enteric materials e.g., cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and the EUDRAGIT® acrylic polymers
- enteric materials which are soluble at higher pH values, are frequently used for colon-specific delivery systems. Due to their pH-dependent attributes and the uncertainty of gastric retention time, in-vivo performance as well as inter- and intra-subject variability are major issues for using enteric coated systems as a time-controlled release of drugs.
- a retarding swellable hydrophilic coating has been used for oral delayed release systems (4,5). It was demonstrated that lag time was linearly correlated with coating weight gain and drug release was pH independent.
- Hydroxypropyl methylcellulose barriers with erodible and/or gellable characteristics formed using press coating technology for tablet dosage forms have been described to achieve time-programmed release of drugs (6).
- bimodal release is characterized by a rapid initial release, followed by a period of constant release, and finalized by a second rapid drug release.
- Tablets or capsules coated with a hydrophobic wax-surfactant layer made from an aqueous dispersion of carnauba wax, beeswax, polyoxyethylene sorbitan monooleate, and hydroxypropyl methylcellulose have been used for rapid drug release after a predetermined lag time. For example,. However, even though a two-hour lag time was achieved for the model drug theophylline at a higher coating level (60%), three hours were required for a complete release of theophylline after the lag time. (8)
- a sustained-release drug delivery system is described in U.S. Pat. No. 4,871,549.
- this system When this system is placed into dissolution medium or the gastrointestinal tract, water influx and the volume expansion of the swelling agent cause the explosion of the water permeable membrane. The drug thus releases after a predetermined time period.
- the OROS® push-pull system (Alza Company) has been developed for pulsatile delivery of water-soluble and water-insoluble drugs ( a specific site (e.g., colon) in the gastrointestinal tract (11).
- the drug formulation is contained within a water-insoluble capsule body and is sealed with a hydrogel plug.
- the capsule cap dissolves in the gastric juice and the hydrogel plug swells.
- the swollen plug is ejected from the PULSINCAP® dosage form and the encapsulated drug is released.
- a pulsatile capsule system containing captopril with release after a nominal 5-hr period was found to perform reproducibly in dissolution and gamma scintigraphy studies. However, in the majority of subjects, no measurable amounts of the drug were observed in the blood, possibly due to instability of the drug in the distal intestine. (12)
- ADDERAL® comprises a mixture of four amphetamine sulfate salts which, in combination is indicated for treatment of Attention Deficit of age.
- One disadvantage of current treatment is that a tablet form is commonly used which many young children have difficulty in swallowing.
- Another disadvantage of current treatments is that two separate doses are administered, one in the morning and one approximately 4-6 hours later, commonly away from home under other than parental supervision. This current form of treatment, therefore, requires a second treatment which is time-consuming, inconvenient and may be problematic for those children having difficulties in swallowing table t formulations.
- the present invention provides an oral multiple pulsed dose delivery system for amphetamine salts and mixtures thereof.
- FIG. 1 illustrates the desired target plasma level profile of the pharmaceutical active contained within the delivery system.
- a pharmaceutical composition for delivering one or more pharmaceutically active amphetamine salts that includes:
- the immediate release and enteric release portions of the composition are present on the same core.
- immediate release and enteric release components are present on different cores.
- composition may include a combination of the hereinabove referred to cores (one or more cores that include both components on the same core and one or more cores that include only one of the two components on the core).
- the present invention provides a composition in which there is immediate release of drug and enteric release of drug wherein the enteric release is a pulsed release and wherein the drug includes one or more amphetamine salts and mixtures thereof.
- the immediate release component releases the pharmaceutical agent in a pulsed dose upon oral administration of the delivery system.
- the enteric release coating layer retards or delays the release of the pharmaceutical active or drug for a specified time period (“lag time”) until a predetermined time, at which time the release of the drug is rapid and complete, i.e., the entire dose is released within about 30-60 minutes under predetermined environmental conditions, i.e. a particular location within the gastrointestinal tract.
- the delay or lag time will take into consideration factors such as transit times, food effects, inflammatory bowel disease, use of antacids or other medicaments which alter the pH of the GI tract.
- the lag time period is only time-dependent, i.e., pH independent.
- the lag time is preferably within 4 to 6 hours after oral administration of the delivery system.
- the present invention is directed to a composition that provides for enteric release of at least one pharmaceutically active amphetamine salt, including at least one pharmaceutically active amphetamine salt that is coated with an enteric coating wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the at least one pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating.
- Typical enteric coating levels did not meet the above requirements for the desired dosage profile of amphetamine salts. Using the typical amount of enteric coating (10-20 ⁇ ) resulted in undesired premature leakage of the drug from the delivery system into the upper gastrointestinal tract and thus no drug delivery at the desired location in the gastrointestinal tract after the appropriate lag time. Thus this coating did not meet the requirements for the drug release profile to provide full beneficial therapeutic activity at the desired time.
- Th is was surprising because an increase in thickness of about 5-10 ⁇ of enteric coatings above a minimum thickness of about 10-20 ⁇ typically does not have a significant effect on release of d rug from within such coatings.
- Enteric coatings typically are pH dependent and will only dissolve/disperse when exposed to the appropriate environment.
- application of a thicker coating greater than 20 ⁇ will only marginally increase the time for complete release at the appropriate environmental condition i.e., for a brief period of time (20 minutes).
- applicants could not achieve the desired result—rather, the coating leaked before the predetermined time in an inappropriate environment resulting in significant loss of the therapeutic agent.
- the pulsed enteric release of the amphetamine salts is accomplished by employing a certain minimum thickness of the enteric coating .
- the pulsed dose delivery comprises a composition which comprises one or more pharmaceutically active amphetamine salts; an enteric coating over the one or more pharmaceutically active amphetamine salts, wherein the thickness of the enteric coating layer is at least 25 ⁇ ; a further layer of one or more pharmaceutically active amphetamine salts over the enteric coating layer; and an immediate release layer coating.
- the thicker enteric coating surprisingly provides the required delayed i m mediate release of the pharmaceutically active amphetamine salt at the desire d time in the desired area of the gastrointestinal tract.
- FIG. 2 illustrates a model of this delivery system.
- the one or more pharmaceutically active amphetamine salts can be provided within or as a part of a core seed around which the enteric coating is applied.
- a core seed can be coated with one or more layers of one or more pharmaceutically active amphetamine salts.
- a delayed immediate release drug delivery can also be accomplished by coating the drug first with a protective layer prior to applying the enteric coating.
- the pulsed enteric release is accomplished by employing a protective layer between the drug and the enteric coating.
- the enteric coating may be of an increased thickness or may be of lower thickness.
- the object of the invention is met by providing a composition comprising one or more pharmaceutically active amphetamine salts; a protective layer coating over the one or more pharmaceutically active amphetamine salt layer(s), and an enteric coating layer over the protective coating layer; a further pharmaceutically active amphetamine salt layer and an immediate release layer coating.
- the thickness of the enteric coating is at least 25 ⁇
- the protective layer comprises an immediate release coating.
- the one or more pharmaceutically active amphetamine salts can be provided within or as a part of a core seed, during the core seed manufacturing process, around which the protective coating is applied.
- a core seed can be coated with one or more layers of one or more pharmaceutically active amphetamine salts.
- the pulsed enteric release is accomplished by employing a protective layer over the enteric coating.
- a pulsed dose release drug delivery system comprising one or more pharmaceutically active amphetamine salts; an enteric coating layer over the pharmaceutically active amphetamine salt layer(s); and a protective layer over the enteric coating; a second pharmaceutically active amphetamine salt layer; and an immediate release layer coating.
- the protective layer is comprised of one or more components, which includes an immediate release layer and a modifying layer.
- the modifying layer is preferably comprised of a semi water-permeable polymer. Applicants have surprisingly found that a semi-permeable polymer coating used in combination with an immediate release layer coating provided a delayed pulsed release drug delivery profile when layered over the enteric coating.
- the protective layer comprises a semi-permeable polymer and an immediate release coating layer.
- the modifying layer comprises a first layer of a semi-permeable polymer which is adjacent to the enteric coating layer and a second coating layer over the semi-permeable polymer coating layer comprising an immediate release polymer coating layer.
- a semi-permeable polymer which may comprise a low water-permeable pH-insensitive polymer, is layered onto the outer surface of the enteric layer, in order to obtain prolonged delayed release time.
- This semi-permeable polymer coating controls the erosion of the pH-sensitive enteric polymer in an alkaline pH environment in which a pH-sensitive polymer will dissolve rapidly.
- Another pH-sensitive layer may be applied onto the surface of a low water-permeability layer to further delay the release time.
- the composition in addition to a protective layer, comprises an acid which is incorporated into the pharmaceutical active layer or coated onto the surface of the active layer to reduce the pH value of the environment around the enteric polymer layer.
- the acid layer may also be applied on the outer layer of the pH-sensitive enteric polymer layer, followed by a layer of low water-permeability polymer. The release of the active thus may be delayed and the dissolution rate may be increased in an alkaline environment.
- the protective coating may be used both over the drug and over the enteric coating.
- the one or more pharmaceutically active amphetamine salts can be provided within or as a part of a core seed, during the core seed manufacturing process, around which the enteric coating is applied.
- a core seed can be coated with one or more layers of one or more pharmaceutically active amphetamine salts.
- the drug delivery system of the present invention as described herein preferably comprises one or a number of beads or beadlets in a dosage form, either capsule, tablet, sachet or other method of orally administering the beads.
- FIG. 1 illustrates a multiple pulse drug delivery system target plasma profile of the drug delivery system of the present invention.
- the profile reflects an immediate-release component followed by a delayed-release component.
- FIG. 2 schematically illustrates the delayed-release system of the present invention.
- FIG. 2a graphically illustrates a pulsed dose delivery system.
- FIGS. 2b and c graphically illustrate the drug release mechanism from the proposed delivery system.
- FIG. 3 is a plot of the percent drug released versus time from the drug-loaded pellets described in Example 1 which exemplifies the immediate release component of the present invention.
- FIG. 4 is a plot of the percent drug released versus time from the coated pellets described in Example 2 which exemplifies the immediate release component and the delayed release components of the present invention.
- FIG. 5 is a plot of the percent drug released versus time from the coated pellets of described in Example 3 which exemplifies the immediate release component and the delayed release components of the present invention.
- FIG. 6 illustrates the drug release profile of coated pellets described in Example 4 which exemplifies the immediate release component and the delayed release components of the present invention.
- the present invention comprises a core or starting seed, either prepared or commercially available product.
- the cores or starting seeds can be sugar spheres; spheres made from microcrystalline cellulose and any suitable drug crystals.
- the materials that can be employed in making drug-containing pellets are any of those commonly used in pharmaceutics and should be selected on the basis of compatibility with the active drug and the physicochemical properties of the pellets.
- the additives except active drugs are chosen below as examples:
- Binders such as cellulose derivatives such as methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer and the like.
- Disintegration agents such as corn starch, pregelatinized starch, cross-linked carboxymethylcellulose (AC-DI-SOL®), sodium starch glycolate (EXPLOTAB®), cross-linked polyvinylpyrrolidone (PLASDONE® XL), and any disintegration agents used in tablet preparations.
- Filling agents such as lactose, calcium carbonate, calcium phosphate, calcium sulfate, microcrystalline cellulose, dextran, starches, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
- Surfactants such as sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, bile salts, glyceryl monostearate, PLURONIC® line (BASF), and the like.
- Solubilizer such as citric acid, succinic acid, fumaric acid, malic acid, tartaric acid, maleic acid, glutaric acid sodium bicarbonate and sodium carbonate and the like.
- Stabilizers such as any antioxidation agents, buffers, acids, and the like, can also be utilized.
- Methods of manufacturing the core include
- Extrusion-Spheronization Drug(s) and other additives are granulated by addition of a binder solution. The wet mass is passed through an extruder equipped with a certain size screen. The extrudates are spheronized in a marumerizer. The resulting pellets are dried and sieved for further applications.
- High-Shear Granulation Drug(s) and other additives are dry-mixed and then the mixture is wetted by addition of a binder solution in a high shear-granulator/mixer. The granules are kneaded after wetting by the combined actions of mixing and milling. The resulting granules or pellets are dried and sieved for further applications.
- Solution or Suspension Layering A drug solution or dispersion with or without a binder is sprayed onto starting seeds with a certain particle size in a fluid bed processor or other suitable equipment. The drug thus is coated on the surface of the starting seeds. The drug-loaded pellets are dried for further applications.
- the core particles have a diameter in the range of about 500 - 1500 100 - 1500 microns; preferably 100-800 microns.
- These particles can then be coated in a fluidized bed apparatus with an alternating sequence of coating layers.
- the core may be coated directly with a layer or layers of at least one pharmaceutically active amphetamine salts and/or the pharmaceutically active amphetamine salt may be incorporated into the core material.
- Pharmaceutical active amphetamine salts contemplated to be within the scope of the present invention include amphetamine base, all chemical and chiral derivatives and salts thereof; methylphenidate, all chemical and chiral derivatives and salts thereof; phenylpropanolamine and its salts; and all other compounds indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
- ADHD attention deficit hyperactivity disorder
- a protective layer may be added on top of t he pharmaceutical active containing layer and also may be provided between active layers.
- a separation or protective layer may be added onto the surface of the active-loaded core, and then the enteric layer is coated thereupon.
- Another active layer may also be added to the enteric layer to deliver an initial dose.
- a protective coating layer may be applied immediately outside the core, either a drug-containing core or a drug-layered core, by conventional coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions.
- Suitable materials for the protective layer include cellulose derivatives such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, ethyl cellulose aqueous dispersions (AQUACOAT®, SURELEASE®), EUDRAGIT® RL 30D, OPADRY® and the like.
- the suggested coating levels are from 1 to 6%, preferably 2-4% (w/w).
- the enteric coating layer is applied onto the cores with or without seal coating by conventional coating techniques, such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions. All commercially available pH-sensitive polymers are included.
- the pharmaceutical active is not released in the acidic stomach environment of approximately below pH 4.5, but not limited to this value. The pharmaceutical active should become available when the pH-sensitive layer dissolves at the greater pH; after a certain delayed time; or after the unit passes through the stomach.
- the preferred delay time is in the range of two to six hours.
- Enteric polymers include cellulose acetate phthalate, Cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters such as, for instance, materials known under the trade name EUDRAGIT® L12.5, L100, or EUDRAGIT® S12.5, S100 or similar compounds used to obtain enteric coatings.
- Aqueous colloidal polymer dispersions or re-dispersions can be also applied, e.g.
- the enteric polymers used in this invention can be modified by mixing with other known coating products that are not pH sensitive.
- coating products include the neutral methacrylic acid esters with a small portion of trimethylammonioethyl methacrylate chloride, sold currently under the trade names EUDRAGIT® and EUDRAGIT® RL; a neutral ester dispersion without any functional groups, sold under the trade names EUDRAGIT® NE30D and EUDRAGIT® NE30; and other pH independent coating products.
- the modifying component of the protective layer used over the enteric coating can include a water penetration barrier layer (semipermeable polymer) which can be successively coated after the enteric coating to reduce the water penetration rate through the enteric coating layer and thus increase the lag time of the drug release.
- a water penetration barrier layer semipermeable polymer
- Sustained-release coatings commonly known to one skilled in the art can be used for this purpose by conventional coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions.
- the following materials can be used, but not limited to: Cellulose acetate, Cellulose acetate butyrate, Cellulose acetate propionate, Ethyl cellulose, Fatty acids and their esters, Waxes, zein, and aqueous polymer dispersions such as EUDRAGIT® RS and RL 30D, EUDRAGIT® NE 30D, AQUACOAT®, SURELEASE®, cellulose acetate latex.
- aqueous polymer dispersions such as EUDRAGIT® RS and RL 30D, EUDRAGIT® NE 30D, AQUACOAT®, SURELEASE®, cellulose acetate latex.
- hydrophilic polymers such as Hydroxyethyl cellulose, Hydroxypropyl cellulose (KLUCEL®, Hercules Corp.), Hydroxypropyl methylcellulose (METHOCEL®, Dow Chemical Corp.), Polyvinylpyrrolidone can also be used.
- An overcoating layer can further optionally be applied to the composition of the present invention.
- OPADRY®, OPADRY II® (Colorcon) and corresponding color and colorless grades from Colorcon can be used to protect the pellets from being tacky and provide colors to the product.
- the suggested levels of protective or color coating are from 1 to 6%, preferably 2-3% (w/w).
- ingredients can be incorporated into the overcoating formula, for example to provide a quicker immediate release, such as plasticizers; acetyltriethyl citrate, triethyl citrate, acetyltributyl citrate, dibutylsebacate, triacetin, polyethylene glycols, propylene glycol and the others; lubricants: talc, colloidal silica dioxide, magnesium stearate, calcium stearate, titanium dioxide, magnesium silicate, and the like.
- composition preferably in beadlet form, can be incorporated into hard gelatin capsules, either with additional excipients, or alone.
- Typical excipients to be added to a capsule formulation include, but are not limited to: fillers such as microcrystalline cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, sorbitol, or any other inert filler.
- fillers such as microcrystalline cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, sorbitol, or any other inert filler.
- there can be flow aids such as fumed silicon dioxide, silica gel, magnesium stearate, calcium stearate or any other material imparting flow to powders.
- a lubricant can further be added if necessary by using polyethylene glycol, leucine, glyceryl behenate, magnesium stearate or calcium stearate.
- the composition may also be incorporated into a tablet, in particular by incorporation into a tablet matrix, which rapidly disperses the particles after ingestion.
- a filler/binder In order to incorporate these particles into such a tablet, a filler/binder must be added to a table that can accept the particles, but will not allow their destruction during the tableting process.
- Materials that are suitable for this purpose include, but are not limited to, microcrystalline cellulose (A VICEL®), soy polysaccharide (EMCOSOY®), pre-gelatinized starches (STARCH® 1500, NATIONAL® 1551), and polyethylene glycols (CARBOWAX®).
- the materials should be present in the range of 5-75% (w/w), with a preferred range of 25-50% (w/w).
- disintegrants are added in order to disperse the beads once the tablet is ingested.
- Suitable disintegrants include, but are not limited to: cross-linked sodium carboxymethyl cellulose (AC-DI-SOL®), sodium starch glycolate (EXPLOTAB®, PRIMOJEL®), and cross-linked polyvinylpolypyrrolidone (Plasone-XL). These materials should be present in the rate of 3-15% (w/w), with a preferred range of 5-10% (w/w).
- Lubricants are also added to assure proper tableting, and these can include, but are not limited to: magnesium stearate, calcium stearate, stearic acid, polyethylene glycol, leucine, glyceryl behanate, and hydrogenated vegetable oil. These lubricants should be present in amounts from 0.1-10% (w/w), with a preferred range of 0.3-3.0% (w/w).
- Tablets are formed, for example, as follows.
- the particles are introduced into a blender along with AVICEL®, disintegrants and lubricant, mixed for a set number of minutes to provide a homogeneous blend which is then put in the hopper of a tablet press with which tablets are compressed.
- the compression force used is adequate to form a tablet; however, not sufficient to fracture the beads or coatings.
- the multiple dosage form of the present invention can deliver rapid and complete dosages of pharmaceutically active amphetamine salts to achieve the desired levels of the drug in a recipient over the course of about 8 hours with a single oral administration.
- the levels of drug in blood plasma of the pharmaceutically active amphetamine salts will reach a peak fairly rapidly after about 2 hours, and after about 4 hours a second pulse dose is released, wherein a second fairly rapid additive increase of plasma drug levels occurs which slowly decreases over the course of the next 12 hours.
- Nonpareil seeds (30/35 mesh, Paulaur Corp., NJ), 6.8 kg were put into a FLM-15 fluid bed processor with a 9′′ Wurster column and fluidized at 60° C.
- the suspension of mixed amphetamine salts (MAS) with 1% HPMC E5 Premium (Dow Chemical) as a binder was sprayed onto the seed under suitable conditions. Almost no agglomeration and no fines were observed with a yield of at least 98%.
- the drug-loaded cores were used to test enteric coatings and sustained release coatings.
- the drug release profile of the drug-loaded pellets of this example is shown in FIG. 3 .
- the following formulation was used to coat the mixed amphetamine salts loaded (MASL) pellets from Example 1 with the EUDRAGIT® L 30D-55 (Rohm Pharma, Germany) coating dispersion.
- 2 kg of MASL pellets were loaded into a fluid bed processor with a reduced Wurster column equipped with a precision coater(MP 2 / 3 , Niro Inc.) .
- the coating dispersion was prepared by dispersing Triethyl citrate, Talc and EUDRAGIT® L 30D-55 into water and mixing for at least 30 minutes. Under suitable fluidization conditions, the coating dispersion was sprayed onto the fluidized MASL pellets. The spraying was continued until the targeted coating level was achieved( 20 ⁇ ) .
- the coated pellets were dried at 30-35° C. for 5 minutes before stopping the process.
- the enteric coated PPA MASL pellets were tested at different pH buffers by a USP paddle method.
- the drug content was analyzed using HPLC. The results showed that the enteric coating delayed the drug release from the coated pellets until after exposure to pH 6 or higher. (Reference # AR98I25-4)
- the drug release profile of the coated pellets of this example is shown in FIG. 4 .
- the following formulation was used to coat the MASL pellets from Example 1 with the EUDRAGIT® 4110D (Rohm Pharma, Germany) coating dispersion.
- MASL pellets (2 kg) were loaded in a fluid bed processor with a reduced Wurster column (GPGC-15 Glatt).
- the coating dispersion was prepared by dispersing Triethyl citrate, Talc and EUDRAGIT® 4110D into water and mixing for at least 30 minutes. Under suitable fluidization conditions, the coating dispersion was sprayed onto the fluidized MASL pellets. The spraying was continued until the targeted coating level was achieved.
- the coated pellets were dried at 30-35° C. for 5 minutes before stopping the process.
- the enteric coated MASL pellets were tested u sing a USP paddle method at different pH buffers. The drug content was analyzed using HPLC. The enteric coating delayed the drug release for several hours from the coated pellets until the pH value reached 6.8 or higher. (Reference # AR98I25-3)
- the drug release profile of coated pellets of this example is shown in FIG. 5 .
- the following formulation was selected to coat the enteric coated MASL pellets.
- Coated MASL pellets from Example 2 or coated MASL pellets from Example 3 (2 kg of either) were loaded into a fluid bed processor with a reduced Wurster column (GPGC-1 5, Glatt).
- the coating dispersion was prepared by mixing SURELEASE® (Colorcon) and water for at least 15 minutes prior to spraying. Under suitable fluidization conditions, the coating dispersion was sprayed onto the fluidized pellets. The spraying was continued until the targeted coating level was achieved.
- the coated pellets were coated with a thin layer of OPADRY® white (Colorcon) (2%) to prevent the tackiness of the coated pellets during storage. The coated pellets were then dried at 35-40° C.
- the drug release profile of the coated pellets from this example is shown in FIG. 6 .
Abstract
Description
-
- (a) one or more pharmaceutically active amphetamine salts that are covered with an immediate release coating, and
- (b) one or more pharmaceutically active amphetamine salts that are covered with an enteric release coating wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the at least one pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating.
TABLE 1 | |||
Ingredients | Amount (%) | ||
Nonpareil seed | 88.00 | ||
mixed amphetamine salts | 11.40 | ||
METHOCEL ® E5 Premium | 0.60 | ||
Water | * | ||
*removed during processing |
TABLE 2 | |||
Ingredients | Amount (%) | ||
MASL pellets | 40.0070.00 | ||
EUDRAGIT ® L 30D-55 | 24.88 | ||
Triethyl citrate | 2.52 | ||
Talc | 2.60 | ||
Water | * | ||
*removed during processing |
TABLE 3 | |||
Ingredients | Amount (%) | ||
MASL pellets | 70.00 | ||
EUDRAGIT ® 4110D | 26.24 | ||
Triethyl citrate | 0.76 | ||
Talc | 3.00 | ||
Water | * | ||
*removed during processing |
TABLE 4 | |||
Ingredients | Amount, kg (%) | ||
Enteric coated MASL pellets | 90.00 | ||
SURLEASE ® | 8.00 | ||
OPADRY ® white | 2.00 | ||
Water | * | ||
*removed during processing |
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/091,011 USRE42096E1 (en) | 1998-10-21 | 2005-03-24 | Oral pulsed dose drug delivery system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/176,542 US6322819B1 (en) | 1998-10-21 | 1998-10-21 | Oral pulsed dose drug delivery system |
US11/091,011 USRE42096E1 (en) | 1998-10-21 | 2005-03-24 | Oral pulsed dose drug delivery system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/176,542 Reissue US6322819B1 (en) | 1998-10-21 | 1998-10-21 | Oral pulsed dose drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE42096E1 true USRE42096E1 (en) | 2011-02-01 |
Family
ID=22644775
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/176,542 Granted US20010055613A1 (en) | 1998-10-21 | 1998-10-21 | Oral pulsed dose drug delivery system |
US09/176,542 Ceased US6322819B1 (en) | 1998-10-21 | 1998-10-21 | Oral pulsed dose drug delivery system |
US11/091,010 Expired - Lifetime USRE41148E1 (en) | 1998-10-21 | 1999-10-20 | Oral pulsed dose drug delivery system |
US09/807,462 Ceased US6605300B1 (en) | 1998-10-21 | 1999-10-20 | Oral pulsed dose drug delivery system |
US10/172,705 Abandoned US20030124188A1 (en) | 1998-10-21 | 2002-06-14 | Oral pulsed dose drug delivery system |
US10/758,417 Abandoned US20040219213A1 (en) | 1998-10-21 | 2004-01-16 | Oral pulsed dose drug delivery system |
US11/091,011 Expired - Lifetime USRE42096E1 (en) | 1998-10-21 | 2005-03-24 | Oral pulsed dose drug delivery system |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/176,542 Granted US20010055613A1 (en) | 1998-10-21 | 1998-10-21 | Oral pulsed dose drug delivery system |
US09/176,542 Ceased US6322819B1 (en) | 1998-10-21 | 1998-10-21 | Oral pulsed dose drug delivery system |
US11/091,010 Expired - Lifetime USRE41148E1 (en) | 1998-10-21 | 1999-10-20 | Oral pulsed dose drug delivery system |
US09/807,462 Ceased US6605300B1 (en) | 1998-10-21 | 1999-10-20 | Oral pulsed dose drug delivery system |
US10/172,705 Abandoned US20030124188A1 (en) | 1998-10-21 | 2002-06-14 | Oral pulsed dose drug delivery system |
US10/758,417 Abandoned US20040219213A1 (en) | 1998-10-21 | 2004-01-16 | Oral pulsed dose drug delivery system |
Country Status (10)
Country | Link |
---|---|
US (7) | US20010055613A1 (en) |
EP (2) | EP1123087B1 (en) |
JP (2) | JP2002527468A (en) |
AT (1) | ATE427101T1 (en) |
AU (1) | AU1214500A (en) |
CA (1) | CA2348090C (en) |
DE (1) | DE69940673D1 (en) |
ES (1) | ES2323910T3 (en) |
HK (1) | HK1038701A1 (en) |
WO (1) | WO2000023055A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9545399B2 (en) | 2012-08-15 | 2017-01-17 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
US9675704B2 (en) | 2006-03-16 | 2017-06-13 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
Families Citing this family (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
JP4613275B2 (en) * | 1998-11-02 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | Multiparticulate modified release composition |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
DE19855421C2 (en) * | 1998-11-02 | 2001-09-20 | Alcove Surfaces Gmbh | Implant |
US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
CA2388560A1 (en) * | 1999-08-31 | 2001-03-08 | Grunenthal Gmbh | Sustained-release form of administration containing tramadol saccharinate |
EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR100748913B1 (en) * | 1999-11-22 | 2007-08-13 | 알자 코포레이션 | Osmotic dosage form comprising first and second |
US6555127B2 (en) * | 2000-01-19 | 2003-04-29 | Pharmaceutical Discovery Corporation | Multi-spike release formulation for oral drug delivery |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
US6500457B1 (en) * | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
CN101317825A (en) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | Controlled release hydrocodone formulations |
CA2440588C (en) | 2001-03-13 | 2010-02-09 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
NZ529308A (en) * | 2001-04-05 | 2005-03-24 | Collagenex Pharm Inc | Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity |
US20020187192A1 (en) * | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
AR034813A1 (en) * | 2001-07-20 | 2004-03-17 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME |
US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
US20030228368A1 (en) * | 2001-09-28 | 2003-12-11 | David Wynn | Edible solid composition and dosage form |
JP2005509605A (en) * | 2001-09-28 | 2005-04-14 | マクニール−ピーピーシー・インコーポレイテッド | A dosage form comprising an edible composition and an edible skin |
US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
PA8578501A1 (en) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20040062778A1 (en) * | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US8999372B2 (en) * | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
CA2507522C (en) * | 2002-12-13 | 2015-02-24 | Durect Corporation | Oral drug delivery system |
US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
US20040208931A1 (en) * | 2002-12-30 | 2004-10-21 | Friend David R | Fast dissolving films for oral administration of drugs |
ATE372112T1 (en) * | 2003-02-10 | 2007-09-15 | Shire Biochem Inc | COMPOSITIONS CONTAINING ENANTIOMERIC AMPHETAMINES FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) |
US20040186180A1 (en) | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
US7749532B2 (en) * | 2003-04-07 | 2010-07-06 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
EP2112920B1 (en) | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US8313775B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
US8313776B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1653925A1 (en) | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
CA2535398C (en) | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
JP5686494B2 (en) | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | Antibiotic preparations, their use and preparation |
JP2007513869A (en) | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
EA013106B1 (en) * | 2003-09-19 | 2010-02-26 | Сан Фарма Адвансед Ресьорч Компани Лтд. | Oral drug delivery system |
WO2005027878A1 (en) | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Delayed released dosage forms |
US10226428B2 (en) | 2003-09-19 | 2019-03-12 | Sun Pharma Advanced Research Company Ltd. | Oral drug delivery system |
US10213387B2 (en) | 2003-09-19 | 2019-02-26 | Sun Pharma Advanced Research Company Ltd. | Oral drug delivery system |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
DE602004030931D1 (en) * | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
WO2005044238A1 (en) * | 2003-11-07 | 2005-05-19 | Ranbaxy Laboratories Limited | Modified release solid dosage form of amphetamine salts |
DE10353186A1 (en) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Multilayer dosage form containing a modulatory substance in relation to the release of active ingredient |
US8067029B2 (en) * | 2004-01-13 | 2011-11-29 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
US7879354B2 (en) | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
JP2005239696A (en) * | 2004-01-30 | 2005-09-08 | Daiichi Suntory Pharma Co Ltd | Medicinal hard capsule preparation blended with inorganic substance |
US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
WO2005117697A2 (en) * | 2004-05-28 | 2005-12-15 | Narayanan Ramasubramanian | Unified indigestion package and process for patient compliance with prescribed medication regimen |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US8715727B2 (en) | 2004-07-02 | 2014-05-06 | Shionogi Inc. | Tablet for pulsed delivery |
CN101849920A (en) * | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | The prolongation that comprises pramipexole or its officinal salt discharges pellet formulation, Its Preparation Method And Use |
RS51527B2 (en) | 2004-08-13 | 2018-02-28 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US9149472B2 (en) * | 2004-08-31 | 2015-10-06 | Jack William Schultz | Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders |
US7350479B2 (en) * | 2004-09-10 | 2008-04-01 | United States Of America As Represented By The Secretary Of The Army | System and method for controlling growth of aquatic plants utilizing bio-eroding means implanted in triploid grass carp |
EP1811975A2 (en) * | 2004-10-19 | 2007-08-01 | The State of Oregon Acting by and | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
US20060088586A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088593A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070281022A1 (en) * | 2004-10-27 | 2007-12-06 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070190133A1 (en) * | 2004-10-27 | 2007-08-16 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US8383159B2 (en) * | 2004-10-27 | 2013-02-26 | Mcneil-Ppc, Inc. | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060087051A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088587A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
GB0427455D0 (en) * | 2004-12-15 | 2005-01-19 | Jagotec Ag | Dosage forms |
EP1830886B1 (en) | 2004-12-27 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
ITBO20050123A1 (en) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA |
US20060204575A1 (en) * | 2005-03-11 | 2006-09-14 | Hengsheng Feng | Amphetamine formulations |
WO2006102965A1 (en) * | 2005-03-29 | 2006-10-05 | Evonik Röhm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance |
JP2008534530A (en) * | 2005-03-29 | 2008-08-28 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | Multiparticulate drug form containing pellets with a substance having a modulating effect on active ingredient release |
JP2008535837A (en) * | 2005-04-06 | 2008-09-04 | マリンクロッド・インコーポレイテッド | Matrix-based pulsed release formulations |
EA200702221A1 (en) * | 2005-04-12 | 2008-04-28 | Элан Фарма Интернэшнл Лимитед | CONTROLLED SHIPPING COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS CONTAINING CEFALOSPORIN |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US20090023778A1 (en) * | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
US20070077300A1 (en) | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US10064828B1 (en) * | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CA2635594A1 (en) * | 2005-12-30 | 2007-07-12 | Advancis Pharmaceutical Corporation | Gastric release pulse system for drug delivery |
US20070196399A1 (en) * | 2006-02-21 | 2007-08-23 | Shin-Etsu Chemical Co., Ltd. | Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine |
CN101453993A (en) | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | Controlled release delivery device comprising an organosol coat |
PL2007362T3 (en) | 2006-04-04 | 2019-02-28 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
US20070238942A1 (en) * | 2006-04-10 | 2007-10-11 | Esophamet Corp. | Apparatus and method for detecting gastroesophageal reflux disease (gerd) |
WO2007121188A2 (en) * | 2006-04-10 | 2007-10-25 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
JP5052602B2 (en) | 2006-05-12 | 2012-10-17 | シャイア エルエルシー | Controlled dose drug delivery system |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
ATE537826T1 (en) | 2006-05-16 | 2012-01-15 | Knopp Neurosciences Inc | COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE |
EP2465500A1 (en) | 2006-05-16 | 2012-06-20 | Knopp Neurosciences, Inc. | Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease |
PE20080907A1 (en) * | 2006-08-31 | 2008-08-22 | Novartis Ag | EXTENDED RELEASE GASTRO-RETENTIVE ORAL DRUG DELIVERY SYSTEM FOR VALSARTAN |
ITMI20061692A1 (en) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA |
CA2666582C (en) * | 2006-10-20 | 2014-09-09 | Mcneil-Ppc, Inc. | Acetaminophen / ibuprofen combinations |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
US20100104621A1 (en) * | 2007-02-21 | 2010-04-29 | Connected Health Systems, Llc | Treating adhd and other diseases involving inflammation |
US8519148B2 (en) * | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
US20080268047A1 (en) * | 2007-04-24 | 2008-10-30 | Xavier University Of Louisiana | Controlled Release Multiple Layer Coatings |
US20080317677A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
US8478862B2 (en) * | 2007-07-13 | 2013-07-02 | Front Porch, Inc. | Method and apparatus for internet traffic monitoring by third parties using monitoring implements |
US7953851B2 (en) * | 2007-07-13 | 2011-05-31 | Front Porch, Inc. | Method and apparatus for asymmetric internet traffic monitoring by third parties using monitoring implements |
EP2044932A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Mechanical protective layer for solid dosage forms |
EP2044929A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Oral fast distintegrating tablets |
CN101842085B (en) | 2007-10-31 | 2013-01-30 | 麦克内尔-Ppc股份有限公司 | Orally disintegrated dosage form |
CA2706658A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition |
EP2227226B1 (en) * | 2007-12-21 | 2016-10-26 | Johnson & Johnson Consumer Inc. | Manufacture of a tablet |
BRPI0908114A2 (en) * | 2008-02-15 | 2015-10-06 | Sun Pharma Advanced Res Co Ltd | controlled release oral tablet |
ES2849873T3 (en) | 2008-04-18 | 2021-08-23 | Intec Pharma Ltd | Administration of carbidopa / levodopa gastroretentive drugs |
EP2309999A1 (en) * | 2008-06-26 | 2011-04-20 | McNeil-PPC, Inc. | Coated particles containing pharmaceutically active agents |
US9009838B2 (en) * | 2008-07-24 | 2015-04-14 | Front Porch, Inc. | Method and apparatus for effecting an internet user's privacy directive |
US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
KR101211338B1 (en) | 2008-11-25 | 2012-12-11 | 닛산 지도우샤 가부시키가이샤 | Conductive member and solid state polymer fuel cell using same |
PL2378883T3 (en) | 2008-12-04 | 2016-06-30 | Intec Pharma Ltd | Zaleplon gastroretentive drug delivery system |
CN102802418A (en) * | 2009-06-19 | 2012-11-28 | 诺普神经科学股份有限公司 | Compositions and methods for treating amyotrophic lateral sclerosis |
PE20120572A1 (en) | 2009-07-22 | 2012-06-06 | Gruenenthal Chemie | HANDLING RESISTANT STABILIZED OXIDATION DOSAGE FORM |
EP2456427B1 (en) | 2009-07-22 | 2015-03-04 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
US8784781B2 (en) | 2009-09-24 | 2014-07-22 | Mcneil-Ppc, Inc. | Manufacture of chewing gum product with radiofrequency |
US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
JP5968300B2 (en) | 2010-03-24 | 2016-08-10 | ジャズ、ファーマシューティカルズ、インコーポレイテッドJazz Pharmaceuticals Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substrates |
ES2689520T3 (en) * | 2010-04-23 | 2018-11-14 | Kempharm, Inc. | Therapeutic formulation to reduce drug side effects |
MX361138B (en) * | 2010-06-16 | 2018-11-28 | Takeda Pharmaceuticals Usa Inc | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors. |
NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
EP4011364B1 (en) * | 2011-03-23 | 2023-12-13 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
EP2726066B1 (en) | 2011-06-28 | 2021-03-31 | Neos Therapeutics, LP | Dosage forms of amphetamine for oral administration |
DK2736497T3 (en) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Shock-resistant tablet that provides an immediate release of a drug. |
EP2736495B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
WO2013059676A1 (en) * | 2011-10-21 | 2013-04-25 | Subhash Desai | Compositions for reduction of side effects |
CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
LT2838512T (en) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
CN105120659A (en) | 2013-03-15 | 2015-12-02 | 度瑞公司 | Compositions with a rheological modifier to reduce dissolution variability |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
LT3019167T (en) | 2013-07-12 | 2021-03-25 | Knopp Biosciences Llc | Treating elevated levels of eosinophils and/or basophils |
WO2015023786A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
PL3033081T3 (en) | 2013-08-13 | 2021-08-30 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CA2936216C (en) | 2014-01-10 | 2021-10-26 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
WO2016138440A1 (en) * | 2015-02-27 | 2016-09-01 | Cingulate Therapeutics LLC | Tripulse release stimulant formulations |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10142086B2 (en) | 2015-06-11 | 2018-11-27 | At&T Intellectual Property I, L.P. | Repeater and methods for use therewith |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US20170296476A1 (en) | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
EP3372225A1 (en) * | 2017-03-09 | 2018-09-12 | Develco Pharma Schweiz AG | Novel dosage form |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
WO2018231619A1 (en) | 2017-06-14 | 2018-12-20 | SpecGx LLC | Delayed sustained release pharmaceutical compositions |
WO2019073028A1 (en) | 2017-10-13 | 2019-04-18 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
JP2022504242A (en) | 2018-11-19 | 2022-01-13 | ジャズ ファーマシューティカルズ アイルランド リミテッド | Alcohol resistant preparation |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2099402A (en) | 1934-01-17 | 1937-11-16 | Pratt Food Company | Pill or tablet |
US2738303A (en) | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US2881113A (en) * | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
US3048526A (en) | 1958-08-04 | 1962-08-07 | Wander Company | Medicinal tablet |
US3066075A (en) * | 1960-07-25 | 1962-11-27 | G W Carnrick Co | Compositions comprising amphetamine and carboxymethyl cellulose in chemically combined form |
US3365365A (en) | 1965-08-09 | 1968-01-23 | Hoffmann La Roche | Repeat action pharmaceutical compositions in the form of discrete beadlets |
US3979349A (en) | 1973-05-07 | 1976-09-07 | Rohm Gmbh | Dispersions of water-soluble polymers and methods for making and using the same |
US4049791A (en) | 1974-06-21 | 1977-09-20 | Delco Chemical Company, Inc. | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents |
JPS5982311A (en) | 1982-11-04 | 1984-05-12 | Shionogi & Co Ltd | Sustained release preparation of cephalexin |
WO1987000044A1 (en) | 1985-07-02 | 1987-01-15 | The Upjohn Company | Therapeutic formulations with bimodal release characteristics |
US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4871549A (en) | 1985-07-19 | 1989-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Time-controlled explosion systems and processes for preparing the same |
US4891230A (en) | 1983-12-22 | 1990-01-02 | Elan Corporation Plc | Diltiazem formulation |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US4902516A (en) | 1987-04-10 | 1990-02-20 | Chemie Holding Aktiengesellschaft | Binder-free granules with delayed release of the active compound |
US4917899A (en) | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
WO1990009168A1 (en) | 1989-02-16 | 1990-08-23 | National Research Development Corporation | Dispensing device |
US5002776A (en) | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US5011694A (en) | 1988-08-11 | 1991-04-30 | Rohm Gmbh | Pharmaceutical dosage unit forms with delayed release |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
JPH03148215A (en) | 1989-11-01 | 1991-06-25 | Nippon Shinyaku Co Ltd | Laminated formulation |
US5051262A (en) | 1979-12-07 | 1991-09-24 | Elan Corp., P.L.C. | Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby |
US5093200A (en) | 1985-10-23 | 1992-03-03 | Eisai Co., Ltd. | Multilayer sustained release granule |
US5137733A (en) | 1990-06-28 | 1992-08-11 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5202159A (en) | 1990-12-27 | 1993-04-13 | Standard Chemical & Pharmaceutical Corp., Ltd. | Preparation method of microdispersed tablet formulation of spray-dried sodium diclofenac enteric-coated microcapsules |
US5226902A (en) | 1991-07-30 | 1993-07-13 | University Of Utah | Pulsatile drug delivery device using stimuli sensitive hydrogel |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5275819A (en) | 1989-02-06 | 1994-01-04 | Amer Particle Technologies Inc. | Drug loaded pollen grains with an outer coating for pulsed delivery |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5328697A (en) * | 1992-02-10 | 1994-07-12 | Mallinckrodt Veterinary, Inc. | Compositions and processes for the sustained release of drugs |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5378474A (en) | 1989-01-06 | 1995-01-03 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
EP0640337A2 (en) | 1993-08-25 | 1995-03-01 | Ss Pharmaceutical Co., Ltd. | Controlled release-initiation and controlled release-rate pharmaceutical composition |
US5395628A (en) | 1989-12-28 | 1995-03-07 | Tanabe Seiyaku Co., Ltd. | Controlled release succinic acid microcapsules coated with aqueous acrylics |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5422121A (en) | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
US5474786A (en) | 1994-03-23 | 1995-12-12 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
WO1997003673A1 (en) | 1995-07-14 | 1997-02-06 | Medeva Europe Limited | Sustained-release formulation of d-threo-methylphenidate |
JPH09249557A (en) | 1996-03-14 | 1997-09-22 | Shionogi & Co Ltd | Sustained release preparation of slightly water-soluble medicine |
JPH09267035A (en) | 1996-01-30 | 1997-10-14 | Kanegafuchi Chem Ind Co Ltd | Production of nuclear particle |
JPH1081634A (en) | 1996-07-18 | 1998-03-31 | Taisho Pharmaceut Co Ltd | Base controlled in dissolution time |
WO1998014168A2 (en) | 1996-09-30 | 1998-04-09 | Alza Corporation | Dosage form providing a sustained and ascending drug release |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6005027A (en) * | 1995-08-16 | 1999-12-21 | Witco Corporation | Stable silane compositions on silica carrier |
WO2000025752A1 (en) | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
WO2000035450A1 (en) | 1998-12-17 | 2000-06-22 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US6475493B1 (en) | 1999-09-02 | 2002-11-05 | Norstrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
US6605300B1 (en) * | 1998-10-21 | 2003-08-12 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
US20040059002A1 (en) | 2002-09-24 | 2004-03-25 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US6749867B2 (en) | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
US6764696B2 (en) | 1998-04-29 | 2004-07-20 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2993836A (en) * | 1958-02-20 | 1961-07-25 | Dow Chemical Co | Sustained release tablets |
NL297631A (en) * | 1963-06-03 | |||
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
KR920702383A (en) * | 1989-08-28 | 1992-09-03 | 원본미기재 | Biocorrosive polymers useful for controlling the release of therapeutic agents |
US5232705A (en) * | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
DE69200476T2 (en) * | 1991-01-30 | 1995-02-02 | Alza Corp | Delayed release osmotic device. |
ATE216577T1 (en) * | 1992-01-29 | 2002-05-15 | Takeda Chemical Industries Ltd | QUICK DISSOLVABLE TABLET AND PRODUCTION THEREOF |
US5322697A (en) * | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
EP0653935B1 (en) * | 1992-08-05 | 2002-05-08 | F.H. FAULDING & CO. LIMITED | Pelletised pharmaceutical composition |
US6103262A (en) | 1994-01-27 | 2000-08-15 | G. D. Searle & Company | Modified-release metronidazole compositions and methods for making and using same |
US5411745A (en) | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US5582855A (en) | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
FR2723536A1 (en) | 1994-08-11 | 1996-02-16 | Seth Pawan | COMPOSITION FOR SELECTIVE RELEASE OF AN ACTIVE INGREDIENT |
US5733575A (en) | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
US5731314A (en) * | 1995-01-06 | 1998-03-24 | Bencherif; Merouane | Pharamceutical compositions for prevention and treatment of tourette's syndrome |
US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5846568A (en) * | 1996-09-19 | 1998-12-08 | Xyrofin Oy | Directly compressible lactitol and method |
HRP970493A2 (en) * | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
US5945123A (en) * | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
CA2368367A1 (en) * | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
-
1998
- 1998-10-21 US US09/176,542 patent/US20010055613A1/en active Granted
- 1998-10-21 US US09/176,542 patent/US6322819B1/en not_active Ceased
-
1999
- 1999-10-20 US US11/091,010 patent/USRE41148E1/en not_active Expired - Lifetime
- 1999-10-20 DE DE69940673T patent/DE69940673D1/en not_active Expired - Lifetime
- 1999-10-20 AU AU12145/00A patent/AU1214500A/en not_active Abandoned
- 1999-10-20 JP JP2000576830A patent/JP2002527468A/en active Pending
- 1999-10-20 CA CA002348090A patent/CA2348090C/en not_active Expired - Lifetime
- 1999-10-20 EP EP99970594A patent/EP1123087B1/en not_active Expired - Lifetime
- 1999-10-20 ES ES99970594T patent/ES2323910T3/en not_active Expired - Lifetime
- 1999-10-20 WO PCT/US1999/024554 patent/WO2000023055A1/en active Application Filing
- 1999-10-20 AT AT99970594T patent/ATE427101T1/en not_active IP Right Cessation
- 1999-10-20 US US09/807,462 patent/US6605300B1/en not_active Ceased
- 1999-10-20 EP EP08157737A patent/EP1977736A1/en not_active Withdrawn
-
2002
- 2002-01-15 HK HK02100312.9A patent/HK1038701A1/en unknown
- 2002-06-14 US US10/172,705 patent/US20030124188A1/en not_active Abandoned
-
2004
- 2004-01-16 US US10/758,417 patent/US20040219213A1/en not_active Abandoned
-
2005
- 2005-03-24 US US11/091,011 patent/USRE42096E1/en not_active Expired - Lifetime
-
2008
- 2008-06-18 JP JP2008159637A patent/JP2008303223A/en not_active Withdrawn
Patent Citations (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2099402A (en) | 1934-01-17 | 1937-11-16 | Pratt Food Company | Pill or tablet |
US2738303A (en) | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US2881113A (en) * | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
US3048526A (en) | 1958-08-04 | 1962-08-07 | Wander Company | Medicinal tablet |
US3066075A (en) * | 1960-07-25 | 1962-11-27 | G W Carnrick Co | Compositions comprising amphetamine and carboxymethyl cellulose in chemically combined form |
US3365365A (en) | 1965-08-09 | 1968-01-23 | Hoffmann La Roche | Repeat action pharmaceutical compositions in the form of discrete beadlets |
US3979349A (en) | 1973-05-07 | 1976-09-07 | Rohm Gmbh | Dispersions of water-soluble polymers and methods for making and using the same |
US4049791A (en) | 1974-06-21 | 1977-09-20 | Delco Chemical Company, Inc. | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents |
US5051262A (en) | 1979-12-07 | 1991-09-24 | Elan Corp., P.L.C. | Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby |
JPS5982311A (en) | 1982-11-04 | 1984-05-12 | Shionogi & Co Ltd | Sustained release preparation of cephalexin |
US5616345A (en) | 1983-12-22 | 1997-04-01 | Elan Corporation Plc | Controlled absorption diltiazen formulation for once-daily administration |
US4891230A (en) | 1983-12-22 | 1990-01-02 | Elan Corporation Plc | Diltiazem formulation |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US4917899A (en) | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
US5002776A (en) | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
WO1987000044A1 (en) | 1985-07-02 | 1987-01-15 | The Upjohn Company | Therapeutic formulations with bimodal release characteristics |
US4871549A (en) | 1985-07-19 | 1989-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Time-controlled explosion systems and processes for preparing the same |
US5093200A (en) | 1985-10-23 | 1992-03-03 | Eisai Co., Ltd. | Multilayer sustained release granule |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4902516A (en) | 1987-04-10 | 1990-02-20 | Chemie Holding Aktiengesellschaft | Binder-free granules with delayed release of the active compound |
US5011694A (en) | 1988-08-11 | 1991-04-30 | Rohm Gmbh | Pharmaceutical dosage unit forms with delayed release |
US5378474A (en) | 1989-01-06 | 1995-01-03 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5275819A (en) | 1989-02-06 | 1994-01-04 | Amer Particle Technologies Inc. | Drug loaded pollen grains with an outer coating for pulsed delivery |
WO1990009168A1 (en) | 1989-02-16 | 1990-08-23 | National Research Development Corporation | Dispensing device |
JPH03148215A (en) | 1989-11-01 | 1991-06-25 | Nippon Shinyaku Co Ltd | Laminated formulation |
US5395628A (en) | 1989-12-28 | 1995-03-07 | Tanabe Seiyaku Co., Ltd. | Controlled release succinic acid microcapsules coated with aqueous acrylics |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5137733A (en) | 1990-06-28 | 1992-08-11 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5422121A (en) | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
US5202159A (en) | 1990-12-27 | 1993-04-13 | Standard Chemical & Pharmaceutical Corp., Ltd. | Preparation method of microdispersed tablet formulation of spray-dried sodium diclofenac enteric-coated microcapsules |
US5226902A (en) | 1991-07-30 | 1993-07-13 | University Of Utah | Pulsatile drug delivery device using stimuli sensitive hydrogel |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5328697A (en) * | 1992-02-10 | 1994-07-12 | Mallinckrodt Veterinary, Inc. | Compositions and processes for the sustained release of drugs |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
JPH0761922A (en) | 1993-08-25 | 1995-03-07 | Ss Pharmaceut Co Ltd | Release start controlling type pharmaceutical preparation |
EP0640337A2 (en) | 1993-08-25 | 1995-03-01 | Ss Pharmaceutical Co., Ltd. | Controlled release-initiation and controlled release-rate pharmaceutical composition |
US5496561A (en) | 1993-08-25 | 1996-03-05 | Ss Pharmaceutical Co., Ltd. | Controlled release-initiation and controlled release-rate pharmaceutical composition |
US5474786A (en) | 1994-03-23 | 1995-12-12 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
WO1997003673A1 (en) | 1995-07-14 | 1997-02-06 | Medeva Europe Limited | Sustained-release formulation of d-threo-methylphenidate |
US6005027A (en) * | 1995-08-16 | 1999-12-21 | Witco Corporation | Stable silane compositions on silica carrier |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
JPH09267035A (en) | 1996-01-30 | 1997-10-14 | Kanegafuchi Chem Ind Co Ltd | Production of nuclear particle |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
JPH09249557A (en) | 1996-03-14 | 1997-09-22 | Shionogi & Co Ltd | Sustained release preparation of slightly water-soluble medicine |
JPH1081634A (en) | 1996-07-18 | 1998-03-31 | Taisho Pharmaceut Co Ltd | Base controlled in dissolution time |
WO1998014168A2 (en) | 1996-09-30 | 1998-04-09 | Alza Corporation | Dosage form providing a sustained and ascending drug release |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
WO1999003471A1 (en) | 1997-07-14 | 1999-01-28 | Mehta, Atul, M. | Improved delivery of multiple doses of medications |
US6764696B2 (en) | 1998-04-29 | 2004-07-20 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US6605300B1 (en) * | 1998-10-21 | 2003-08-12 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
WO2000025752A1 (en) | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
WO2000035450A1 (en) | 1998-12-17 | 2000-06-22 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US6475493B1 (en) | 1999-09-02 | 2002-11-05 | Norstrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
US6749867B2 (en) | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
US20040059002A1 (en) | 2002-09-24 | 2004-03-25 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
Non-Patent Citations (156)
Title |
---|
Adderall XR Package Inset, Sep. (2004). |
Agyilirah GA and Bauker SB, Polymers for Enteric Coating Applications, Polymers for Controlled Drug Delivery (Peter J. Tarcha ed. 1991) 39-66. |
American Chemical Society, Polymer Preprints, pp. 633-634, vol. 34, No. 1, Mar. 1993. |
Angrist et al., Early Pharmacokinetics and Clinical Effects of Oral D-Amphetamine in Normal Subjects, Biol. Psychiatry 1987, 22: 1357-1368. |
Ansel, et al., Rate Controlled Dosage Forms and Drug Delivery Systems, Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th Ed. (1995), 213-222. |
Answer and Counterclaims in Shire Laboratories, Inc. v. Andrx, LLC, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07-22201-CIV-Cooke/Brown, Aug. 31, 2007. |
Answering Expert Report of Dr. Alexander Klibanov, Apr. 25, 2005. |
Answering Expert Report of Robert Langer, Apr. 25, 2005. |
Barr Laboratories Inc.'s Objections and Responses to Shire Laboratories Inc.'s Second Set of Interrogatories (Nos. 8-11), dated Feb. 18, 2004. |
Barr Laboratories' Memorandum In Support of its Motion to Amend its Pleadings and exhibits thereto, dated Sep. 10, 2004. |
Barr Laboratories' Memorandum in Support of its Motion to Compel Production, dated Sep. 13, 2004. |
Barr Laboratories' Objections and Responses to Plaintiff Shire Laboratories Inc.'s Fifth Set of Interrogatories (No. 17), dated Sep. 3, 2004. |
Barr Laboratories' Objections and Responses to Plaintoff Shire Laboratories Inc.'s Fourth Set of Interrogatories (Nos. 15-16), dated Jul. 9, 2004. |
Barr Laboratories' Supplemetal Objections and Responses to Plaintiff Shire Laboratories Inc.'s Third Set of Interrogatories (Nos. 12-14 Redacted), dated Aug. 27, 2004. |
Bauer, et al., Cellulose Acetate Phthalate (CAP) and Trimellitate (CAT), Coated Pharmaceutical Dosage Forms (1998), 102-104. |
Bodmeier et al., The Influence of Buffer Species and Strength on Diltiazem HCl Release from Beads Coated with the Aqueous Catinoc Polymer Dispensions, Eudragit RS, RL 30D, Pharmaceutical Research vol. 13, No. 1, 1996, 52-56. |
Brauer et al., Acute Tolerance to Subjective but not Cardiovascular Effects of d-Amphetamine in normal, Healthy Men, Journal of Clinical Psychopharmacology, 1996; 16(1):73-76. |
Brown et al., Behavior and Motor Activity Response in Hyperactive Children and Plasma Amphetamine Levels Following a Sustained Release Preparation, Journal of the American Academy of Child Psychiatry, 19:225-239, 1980. |
Brown et al., Plasma Levels of d-Amphetamine in Hyperactive Children, Psychopharmacology 62, 133-140, 1979. |
Burns et al., A study of Enteric-coated Liquid-filled Hard Gelatin Capsules with Biphasic Release Characteristics, International Journal of Pharmaceutics 110 (1994) 291-296. |
Burnside Deposition Transcript, Feb. 2, 2005. |
Burnside Deposition Transcript, Feb. 3, 2005. |
C. Lin et al., Biovailability of d-pseudoephedrine and Azatadine from a Repeat Action Tablet Formulation, J Int Med Res (1982), 122-125. |
C. Lin et al., Comparative Biovailability of d-pseudoephedrine from a Conventional d-pseudoephedrine Sulfate Tablet and from a Repeat Action Tablet, J Int Med Res (1982) 10, 126-128. |
Chan, Materials Used for Effective Sustained-Release Products, Proceedings of the International Symposium held on 29th to 31st of Jan. 1987 (The Bombay College of Pharmacy 1988), 69-84. |
Chan, New Polymers for Controlled Release Products, Controlled Release Dosage Forms Proceedings of the International Symposium held on 29th to 31st of Jan. 1987 (The Bombay College of Pharmacy 1988) 59-67. |
Chang Deposition Transcript, Jan. 20, 2005. |
Chang Deposition Transcript, Sep. 8, 2004. |
Chang et al., Preparation and Evaluation of Shellac Pseudolatex as an Aqueous Enteric Coating Systems for Pellets, International Journal of Pharmaceuticals, 60 (1990) 171-173, 1990. |
Charles S.L. Chlao amd Joseph R. Robinson, Sustained-Release Drug Delivery Systems, Remington: The Science and Practice of Pharmacy, Tenth Edition (1995) 1660-1675. |
Cody et al., Amphetamine Enantiomer Excretion Profile Following Administration of Adderall, Journal of Analytical Toxicology, vol. 2, Oct. 2003, 485-492. |
Complaint for Declaratory Judgment, Impax Laboratories Inc. v. Shire International Laboratories, Inc. (Civ. Action No. 05772) and Exhibits attached thereto, dated Nov. 9, 2005. |
Conte, et al., "Press-coated tablets for time-programmed release of drugs," Biomaterials, 14(13):1017-1023 (1993). |
Couch Deposition Transcript, Sep. 8, 2004. |
Daynes, Treatment of Noctural Enuresis with Enteric-Coated Amphetamine, The Practitioner, No. 1037, vol. 173, Nov. 1954. |
Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire LLC's Interrogatories (No. 1-9), in the United States District Court for the District of Colorado, Case No. 07-CV-001197-EWN-CBS, Jun. 18, 2007. |
Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire LLC's Second Set of Interrogatories (No. 10-19), in the United States District Court for the District of Colorado, Case No. 07-CV-001197-EWN-CBS, Nov. 20, 2007. |
Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire LLC's Second Set of Interrogatories (No. 20-25) and Supplement to Answers to Interrogatories 8 and 9, in the United States District Court for the District of Colorado, Case No. 07-CV-001197-EWN-CBS, Dec. 10, 2007. |
Deposition transcript of Honorable Gerald J. Mossinghoff and exhibits thereto, dated Jun. 8, 2005. |
Edward Stempel, Prolonged Drug Action, HUSA's Pharmaceutical Dispensing, Sixth Edition, 1966, 464, 481-485. |
Expert Report of Arthur J. Steiner in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, case No. 1:07-cv-00718, Dec. 20, 2007. |
Expert Report of Dr. Joseph R. Robinson and exhibits thereto, Feb. 28, 2005. |
Expert Report of the Honorable Gerald J. Mossinghoff and exhibits thereto, Mar. 16, 2005. |
Fiske Deposition Transcript, Sep. 17, 2004. |
Freedom of Information Request Results for—Dexadrine (SmithKline Beecham): May 20, 1976 Disclosable Approval Information. |
Fukumori, Coating of Multiparticulates Using Polymeric Dispersions, Multiparticulate Oral Drug Delivery (Swarbrick and Selassie eds. 1994), 79-110. |
Garnett et al., Pharmacokinitic Evaluation of Twice-Daily Extended-Release Carbamazepine (CBZ) and Four-Times-Daily Immediate-Release CBZ in Patients with Epilepsy, Epilepsia 39(3):274-279, 1998. |
Gazzaniga, et al., "Oral Chronotopic Drug Delivery Systems: Achievement of Time and/or Site Specificity," Eur. J. Pharm. Biopharma 40(3):246-250 (1994). |
Gazzaniga, et al., "Time-dependent oral delivery systems for colon targeting," S.T.P. Pharma Sciences, 5(1):83-88 (1995). |
Ghebre-Sellassie et ., "Evaluation of acrylic-based modified-release film coatings," International Journal of Pharmaceutics, 1987;37:211-218. |
Goodhart et al., An Evaluation of Aqueous Film-Forming Dispersions for Controlled Release, Pharmaceutical Technology, Apr. 1984. |
Greenhill et al., A Pharmacokinetic/Pharmacodynamic Study Comparing a Single Morning Dose of Adderall to Twice-Daily Dosing in Children with ADHD. J. Am. Acad. Adolesc. Psychiatry, 42:10, Oct. 2003. |
Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations (1997). |
Guidance for Industry: Food-Effext Bioavailability and Fed Bioequivalence Studies (2002). |
Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms (1997). |
Guo Deposition Transcript, Jan. 24, 2005. |
Guo Deposition Transcript, Jul. 26, 2004. |
Hall HS and Pondell RE, Controlled Release Technologies: Method, Theory, and Applications, pp. 133-154 (Agis F. Kydonieus ed. 1980). |
Handbook of Pharmaceutical Excipients: Ethylcellulose, Polymethacrylates, (4th ed. (2003), 237-240, 462-468. |
Handbook of Pharmaceutical Excipients: Plymethacrylates, (2nd ed. 1994), 361-366. |
Hans-Martin Klein & Rolf W. Gunther, Double Contrast Small Bowell Follow-Through with an Acid-Resistant Effervescent Agent, Investigative Radiology vol. 28, Jul. 1993. |
Harrington Deposition Transcript, Jul. 27, 2005. |
Harris et al., Aqueous Polymeric Coating for Modified-Release Pellets, Aqueous Polymeric Coating for Pharmaceutical Dosage Forms (McGinity ed., 1989). |
Hawley's Condensed Chemical Dictionary 13th Ed. 1997, 584, 981. |
Holt, Bioequivalence Studies of Ketoprofen: Product formulation, Pharmacokinetics, Deconvolution, and In Vitro-In Vivo correlations, Thesis submitted to Oregon State University, Aug. (1997). |
Husson et al., Influence of Size Polydispersity on Drug Release from Coated Pellets, International Journal of Pharmaceutics, 86 (1992) 113-121, 1992. |
Impax Laboratories Inc.'s First Amended Answer and Affirmative Defenses, dated May 2, 2005. |
Impax Laboratories, Inc.'s First Supplemental Responses to Shire Laboratories Inc.'s First Set of Interrogatories (Nos. 11-12). |
Impax Laboratories, Inc.'s Memorandum in Support of the Motion to Amend its Answer dated Feb. 25, 2005 and exhibits thereto. |
Impax Laboratories, Inc.'s Reply Memorandum in Support of the Motion to Amend its Answer dated Mar. 18, 2005 and exhibit thereto. |
Interview Summary U.S. Appl. No. 11/091,010 filed date Dec. 22, 2008. |
Ishibashi et al., Design and Evaluatin of a New Capsule-type Dosage Form for Colon-Targeted Delivery of Drugs, International Journal of Pharmaceutics 168, (1998) 31-40, 1998. |
J. Sjogren, Controlled release oral formulation technology, Rate Control in Drug Therapy, (1985) 38-47. |
Jarowski, The Pharmaceutical Pilot Plant, Pharmaceutical Dosage Forms: Tablets, vol. 3, 2nd Ed. (1990), 303-367. |
Judgment and Order of Permanent Injunction in Shire LLC v. Teva Pharmaceutical Industries Ltd. in the United States District Court for the Eastern District of Pennsylvania, Civil Action No. 06-952-SD, Mar. 6, 2008. |
Judgment and Order of Permanent Injuunction in Shire Laboratories, Inc. v. Andrx Pharmaceuticals, LLC, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07-22201-CIV-Cooke/Brown, Nov. 19, 2007. |
Kao et al., Lag Time Method to Delay Drug Release to Various Sites in the Gastrointestinal Tract, Journal of Controlled Release 44(1997) 263-270. |
Kennerly S. Patrick & John S. Markowitz, Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit Hyperactivity Disorder, Human Psychopharmacology, vol. 12, 527-546 (1997). |
Kiriyama et al., The Bioavailability of Oral Dosage Forms of a New HIV-1 Protease Inhibitor, KNI-272, in Beagle Dogs, Biopharmaceutics & Drug Disposition, vol. 17 125-234 (1996). |
Klaus Lehmann, Coating of Multiparticulates Using Polymeric Solutions, Multiparticulate Oral Drug Delivery (Swarbrick and Sellassie ed., 1994). |
Krowczynski & Brozyna, Extended-Release Dosage Forms, pp. 123-131 (1987). |
Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig, The Theory and Practice of Industrial Pharmacy, Second Edition (1976) 371-373. |
Leopold & Eikeler, Eudragit E as Coating Material for the pH-Controlled Drug Release in the Topical Treatment of Inflammatory Bowel Disease (IBD), Journal of Drug Targeting, 1998, vol. 6, No. 2, pp. 85-94. |
Lin & Cheng, In-vitro Dissolution Behaviour of Spansule-type Micropellets Prpared by Pan Coating Method, Pharm. Ind. 51 No. 5 (1989). |
Liu et al., Comparative Release of Phenylprepanolamine ECl from Long-Acting Appetite Suppressant Product: Acutrim vs. Dexatrim, Drug Development and Industrial Pharmacy, 10(10), 1639-1661 (1984). |
Marcotte et al., Kinetics of Protein Diffusion from a Poly(D,L-Lactide) Reservoir System, Journal of Pharmaceutical Sciences vol. 79, No. 5, May 1990. |
Mathir et al., In vitro characterization of a controlled-release chlorpheniramine maleate delivery system prepared by the air-suspension technique, J. Microencapsulation, vol. 14, No. 6,743-751 (1997). |
McGough et al., Pharmacokinetics of SL1381 (Adderall XR), an Extended-Release Formulation of Adderall, Journal of the American Academy of Child & Adolescent Psychiatry, vol. 42, No. 6, Jun. 2003. |
McGraw-Hill Dictionary of Scientific and Technical Terms, 5th Ed. (1994), 97, 972. |
McGuiness Deposition Transcript, Aug. 6, 2004. |
Mehta et al., Evaluation of Fluid-bed Processes for Enteric Coating Systems, Pharmaceutical Technology, Apr. 1986. |
Moller, Dissolution Testing of Delayed Release Preparations, Proceedings of the International Symposium held on 29th to 31st of Jan. 1987 (The Bombay College of Pharmacy 1988), 85-11. |
Notice of Allowance in U.S. Appl. No. 11/091,011 dated Jul. 20, 2007. |
Notice of Allowance U.S. Appl. No. 11/091,010 filed dated Dec. 22, 2008. |
Opening Expert Report of Dr. Michael Mayersohn and exhibits thereto, Mar. 12, 2005. |
Opening Expert Report of Dr. Walter Chambliss and exhibits thereto, Mar. 15, 2005. |
Order and Memorandum Denying Colony's Motion for Partial Summary Judgment of Noninfringement of the '819 and '300 Patents in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. CCB-07-718, Jan. 2, 2008. |
Ozturk et al., "Kinetics of Release from Enteric-Coated Tablets," Pharmacutical Research 1988;5:550-565. |
PDR Drug Information for Ritalin LA Capsules, Apr. (2004). |
Pelham et al., A Comparison of Morning-Only and Morning/Late Afternoon Adderall to Morning-Only, Twice-Daily, and Three Times-Daily Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder, Pediatrics, vol. 104, No. 6, Dec. 1999. |
Petition to Withdraw Application from Issue Pursuant to 37 CFR 1.313(c)(2) dated Oct. 16, 2007. |
Physicians' Desk Reference: Adderall, 51st Ed. (1997). |
Physicians' Desk Reference: Adderall, 56th Ed. (2002). |
Physicians' Desk Reference: Dexedrine 56th Ed. (2002). |
Physicians' Desk Reference: Ritalin, 56th Ed. (2002). |
Plaintiff Shire LLC's Responses to Interrogatories No. 1-13 in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07-cv-00718-CCB, Jun. 6, 2007. |
Plaintiffs Shire Laboratories, Inc.'s and Shire LLC's Reply to Defendant Andrx Pharmaceuticals, LLC's Counterclaims, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07-22201-CIV-Cooke/Brown, Sep. 24, 2007. |
Pozzi, et al, The Time Clock system: a new oral dosage form for fast and complete release of drug after a predetermined lag time,: Journal of Controlled Release, 31:99-108 (1994). |
Prescribing Information: Dexedrine, brand of dextroamphetamine sulfate (2001). |
R. Bianchini & C. Vecchio, Oral Controlled Release Optimization of Pellets Prepared by Extrusion-Spheronization Processing, IL Farmaco 44(6), 645-654, 1989. |
Rambali, et al., Using experimental design to optimize the process parameters in fluidized bed granulation on a semi-full scale, International Journal of Pharmaceutics 220 (2001) 149-160. |
Remington: The Science and Practice of Pharmacy, Basic Pharmacokinetics, 16th Ed. (1980), 693. |
Remington: The Science and Practice of Pharmacy, Elutriation, 20th Ed. (2000), 690. |
Remington's Pharmaceutical Sciences, Fifteenth Edition (1975) 1624-1625. |
Rong-Kun Chang and Joseph R. Robinson, Sustained Drug Release from Tablets and Particles Through Coating, Pharmaceutical Dosage Forms: Tablets (Marcel Dekker, Inc. 1990), 199-302. |
Rong-Kun Chang, A Comparison of Rheological and Enteric Properties among Organic Solutions, Ammonium Salt Aqueous Solutions, and Latex Systems of Some Enteric Polymers, Pharmaceutical Technology, Oct. 1990. |
Rosen et al., Absorption and Excretion of Radioactively Tagged Dextroamphetamine Sulfate from a Sustained-Release Preparation, Jama, vol. 194, No. 11, Dec. 13, 1965, 145-147. |
Rosen, et al., Absorption and Excretion of Radioactively Tagged Dextroamphetamine Sulfate From a Sustained-Release Preparation, Journal of the American Medical Association, Dec. 13, 1965, vol. 194, No. 11, 1203-1205. |
Rudnic Deposition Transcript, Jul. 28, 2004. |
Schaffer Deposition Transcript, Aug. 17, 2005. |
Scheiffele, et al., Studies Comparing Kollicoat MAE 30 D with Commercial Cellulose Derivatives for Enteric Coating on Caffiene Cores, Drug Development and Industrial Pharmacy, 24(9), 807-818 (1998), 807-818. |
Second Amended Complaint for Patent Infringement and Declaratory Relief in Shire Laboratories, Inc. v. Andrx Pharmaceuticals, LLC, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07-22201-CIV-Cooke/Brown, Nov. 15, 2007. |
Serajuddin, et al., Selection of Solid Dosage Form Composition through Drug-Excipient Compatibility Testing, Journal of Pharmaceutical Sciences vol. 88, No. 7, Jul. 1999, 696-704. |
Shargel;. Pharmacokinetics of Oral Absorption, Applied Biopharmaceutics & Pharmacokinetics. 5th Ed. (2005), 164-166. |
Sheen et al., Aqueous Film Coating Studies of Sustained Release Nicotinic Acid Pellets: An In-Vitro Evaluation, Drug Development and Industrial Pharmacy, 18(8), 851-860 (1992). |
Shire Laboartories Inc.'s Opposition to Barr Laboratories' Motion to Amend Its Answers and Counterclaims, Sep. 15, 2004. |
Slattum, et al., Comparison of Methods for the Assessment of Central Nervous System Stimulant Response after Dextroamphetamine Administration to Healthy Male Volunteers, J. Clin Pharmacol 1996; 36: 1039-1050. |
Sprowls' American Pharmacy: An Introduction to Pharmaceutical Techniques and Dosage Forms, 7th Ed. (1974), 387-388. |
Sriamornsak, et al., Development of sustained release theophylline pellets coated with calcium pectinate, Journal of Controlled Release 47 (1997) 221-232. |
Stevens, et al., Controlled, Multidose, Pharmacokinetic Evaluation of Two Extended-Release Carbamazepine Formulations (Carbatrol and Tegretol-XR), Journal of Pharmaceutical Sciences vol. 87, No. 12, Dec. 1998, 1531-1534. |
Supplemental Expert Report of Harry G. Brittain, PhD, FRSC in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07-cv-00718, Feb. 15,2008. |
Teva Notice letter: Feb. 21, 2005. |
Teva Notice letter: Jun. 1, 2005. |
The Merck Index: Amphetamine, 12th Ed., 620. |
The Merck Index: Amphetamine, 13th Ed., (2001), 97, 1089. |
The United States Pharmacopeia 23, National Formulary 18 (1995) pp. 1791-1799. |
The United States Pharmacopeia 26, National Formulary 21 (2003) pp. 2157-2165. |
The United States Pharmacopeia 27, National Formulary 22 (2004) pp. 2302-2312. |
Transcrip of Richard A. Couch 30(b)(6) Deposition in Shire LLC vs. Sandoz Inc. in the United States District Court for the District of Colorado, Dec. 14, 2007. |
Transcript of Beth A. Burnside Deposition in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07-cv-00718-CCB, Nov. 9, 2007. |
Transcript of Beth A. Burnside Deposition in Shire LLC vs. Sandoz Inc. in the United States District Court for the District of Colorado, Case No. 07-CV-001197-EWN-CBS, Nov. 30, 2007. |
Transcript of Kimberly Fiske Farrand Deposition in Shire, LLC v. Sandoz, Inc. in the United States District Court of Colorado, Dec. 4, 2007. |
Transcript of Richard A. Couch Deposition in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07-cv-00718-CCB, Nov. 15, 2007. |
Transcript of richard Rong-Kun Chang in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07-cv-00718-CCB, Nov. 20, 2007. |
Treacy Deposition Transcript, Aug. 31, 2004. |
Treatise on Controlled Drug Delivery, pp. 185-199 (Agis Kydonieus ed. 1992). |
Tulloch, et al., SL1381 (Adderall XR), a Two-component, Extended-Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test formulations and Comparison of Fasted, Fed, and Sprinkled Administration, PHARMACOTHERAPY vol. 22, No. 11. (2002), 1405-1415. |
US 6,034,101, 3/2000, Gupta et al. (withdrawn) |
Vasilevska, et al., Preparation and Dissolution Characteristics of Controlled Release Diltiazem Pellets, Drug Development and Industrial Pharmacy, 18(15), 1649-1661 (1992). |
Walia et al., "Preliminary Evaluation of an Aqueous Wax Emulsion for Controlled-Release Coating," Pharmaceutical Development and Technology, 3(1):103-113-(1998). |
Watano, et al., Evaluation of Aqueous Enteric Coated Granules Prepared by Moisture Control Method in Tumbling Fluidized Bed Process, Chem. Pharm. Bull. 42(3) 663-667 (1994). |
Wesdyk, et al., Factors affecting differences in film thickness of beads coated in fluidized bed units, International Journal of Pharmaceutics, 93 101-109, (1993). |
Wigal, et al., Evaluation of Individual Subjects in the Analog Classroom Setting; II. Effects of dose of amphetamine (Adderall), Psychopharmacology Bulletin, vol. 34, No. 4, pp. 833-838, 1998. |
Wilding, et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation," Pharmaceutical Research, 9(5):654-657 (1992). |
Wouessidjewe, Aqueous polymethacrylate Dispersions as Coating Materials for Sustained and Enteric Release Systems, S.T.P. Pharma Sciences 7(6) 469-475 (1997). |
Xin Xu and Ping I. Lee, "Programmable Drug Delivery from an Erodible Association Polymer System," Pharmaceutical Research, 10(8):1144-1152 (1993). |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9675704B2 (en) | 2006-03-16 | 2017-06-13 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
US9675703B2 (en) | 2006-03-16 | 2017-06-13 | Tris Pharma, Inc | Modified release formulations containing drug - ion exchange resin complexes |
US10086087B2 (en) | 2006-03-16 | 2018-10-02 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
US9545399B2 (en) | 2012-08-15 | 2017-01-17 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
US9844544B2 (en) | 2012-08-15 | 2017-12-19 | Tris Pharma, Inc | Methylphenidate extended release chewable tablet |
US9844545B2 (en) | 2012-08-15 | 2017-12-19 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
US11633389B2 (en) | 2012-08-15 | 2023-04-25 | Tris Pharma, Inc | Methylphenidate extended release chewable tablet |
US11103494B2 (en) | 2012-08-15 | 2021-08-31 | Tris Pharma, Inc | Methylphenidate extended release chewable tablet |
US11103495B2 (en) | 2012-08-15 | 2021-08-31 | Tris Pharma, Inc | Methylphenidate extended release chewable tablet |
US10857143B2 (en) | 2012-08-15 | 2020-12-08 | Tris Pharma, Inc | Methylphenidate extended release chewable tablet |
US10507203B2 (en) | 2012-08-15 | 2019-12-17 | Tris Pharma, Inc | Methylphenidate extended release chewable tablet |
US10507186B2 (en) | 2014-10-31 | 2019-12-17 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10111839B2 (en) | 2014-10-31 | 2018-10-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10449159B2 (en) | 2014-10-31 | 2019-10-22 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512613B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512612B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10568841B2 (en) | 2014-10-31 | 2020-02-25 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10688060B2 (en) | 2014-10-31 | 2020-06-23 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11896722B2 (en) | 2014-10-31 | 2024-02-13 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10292938B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10292939B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10500162B2 (en) | 2014-10-31 | 2019-12-10 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Also Published As
Publication number | Publication date |
---|---|
EP1123087A1 (en) | 2001-08-16 |
DE69940673D1 (en) | 2009-05-14 |
EP1123087B1 (en) | 2009-04-01 |
EP1123087A4 (en) | 2004-02-11 |
AU1214500A (en) | 2000-05-08 |
USRE41148E1 (en) | 2010-02-23 |
US20030124188A1 (en) | 2003-07-03 |
ATE427101T1 (en) | 2009-04-15 |
WO2000023055A9 (en) | 2000-08-31 |
US6322819B1 (en) | 2001-11-27 |
US20040219213A1 (en) | 2004-11-04 |
ES2323910T3 (en) | 2009-07-27 |
HK1038701A1 (en) | 2002-03-28 |
JP2002527468A (en) | 2002-08-27 |
EP1977736A1 (en) | 2008-10-08 |
CA2348090A1 (en) | 2000-04-27 |
US6605300B1 (en) | 2003-08-12 |
US20010055613A1 (en) | 2001-12-27 |
JP2008303223A (en) | 2008-12-18 |
WO2000023055A1 (en) | 2000-04-27 |
CA2348090C (en) | 2004-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42096E1 (en) | Oral pulsed dose drug delivery system | |
JP6815358B2 (en) | Timed pulse emission system | |
US20180344669A1 (en) | Controlled dose drug delivery system | |
CA2651890C (en) | Controlled dose drug delivery system | |
JP2012525444A (en) | Orally disintegrating tablet composition comprising a combination of high and low dose drugs | |
WO2010036975A2 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
AU2006236052B2 (en) | Oral pulsed dose drug delivery system | |
AU2004200325B2 (en) | Oral Pulsed Dose Drug Delivery System | |
AU2013273835A1 (en) | Timed, pulsatile release systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHIRE LABORATORIES, INC., MARYLAND Free format text: RELEASE OF SECURITY INTEREST UNDER THE AMENDED AND RESTATED CREDIT AGREEMENT;ASSIGNOR:DLJ CAPITAL FUNDING, INC. AS ADMINISTRATIVE AGENT;REEL/FRAME:016914/0056 Effective date: 20040910 |
|
AS | Assignment |
Owner name: SHIRE LLC, KENTUCKY Free format text: MERGER;ASSIGNOR:SHIRE LABORATORIES, INC.;REEL/FRAME:018648/0711 Effective date: 20061215 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 12 |
|
IPR | Aia trial proceeding filed before the patent and appeal board: inter partes review |
Free format text: TRIAL NO: IPR2015-02009 Opponent name: AMERIGEN PHARMACEUTICALS LIMITED Effective date: 20151001 |
|
IPR | Aia trial proceeding filed before the patent and appeal board: inter partes review |
Free format text: TRIAL NO: IPR2016-01033 Opponent name: MYLAN PHARMACEUTICALS INC.,MYLAN INC. AND MYLAN N. Effective date: 20160512 |
|
IPRC | Trial and appeal board: inter partes review certificate |
Kind code of ref document: K1 Free format text: INTER PARTES REVIEW CERTIFICATE; TRIAL NO. IPR2015-02009, OCT. 1, 2015INTER PARTES REVIEW CERTIFICATE FOR PATENT RE42,096, ISSUED FEB. 1, 2011, APPL. NO. 11/091,011, MAR. 24, 2005INTER PARTES REVIEW CERTIFICATE ISSUED FEB. 23, 2018 Effective date: 20180223 |